JP-2025515485-A5 -

Dates

Publication Date

20260508

Application Date

20230428

Description

Equivalents Those skilled in the art will recognize many equivalents to the specific embodiments of the invention described herein, or can confirm them by mere ordinary experimentation. Such equivalents are intended to be covered by the following claims. The present invention includes, for example, the following embodiments: [1] A method for treating a hereditary retinal disease in a human patient, comprising administering to the patient via intravitreal injection a composition containing about 1 mg to about 10 mg of anti-C1q antibody, The method wherein the antibody comprises a light chain variable domain having HVR-L1 having the amino acid sequence of SEQ ID NO: 5, HVR-L2 having the amino acid sequence of SEQ ID NO: 6, and HVR-L3 having the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable domain having HVR-H1 having the amino acid sequence of SEQ ID NO: 9, HVR-H2 having the amino acid sequence of SEQ ID NO: 10, and HVR-H3 having the amino acid sequence of SEQ ID NO: 11. [2] The method according to [1], wherein the hereditary retinal disease is retinitis pigmentosa. [3] The method according to [1], wherein the hereditary retinal disease is colloideremia. [4] The method according to [1], wherein the hereditary retinal disease is Stargardt disease. [5] The method according to [1], wherein the hereditary retinal disease is cone-rod dystrophy. [6] The method according to [1], wherein the hereditary retinal disease is Leber congenital amaurosis. [7] The method according to [1], wherein the hereditary retinal disease is X-linked RP. [8] The method according to [1], wherein the hereditary retinal disease is Usher syndrome. [9] A method for treating retinal detachment in a human patient, comprising administering to the patient via intravitreal injection a composition containing about 1 mg to about 10 mg of anti-C1q antibody, The method wherein the antibody comprises a light chain variable domain having HVR-L1 having the amino acid sequence of SEQ ID NO: 5, HVR-L2 having the amino acid sequence of SEQ ID NO: 6, and HVR-L3 having the amino acid sequence of SEQ ID NO: 7, and a heavy chain variable domain having HVR-H1 having the amino acid sequence of SEQ ID NO: 9, HVR-H2 having the amino acid sequence of SEQ ID NO: 10, and HVR-H3 having the amino acid sequence of SEQ ID NO: 11. [10] The method according to [9], wherein the anti-C1q antibody is administered before retinal detachment surgery. [11] The method according to [9], wherein the anti-C1q antibody is administered after retinal detachment surgery. [12] The method according to [9], wherein the anti-C1q antibody is administered at the same time as retinal detachment surgery. [13] The method according to any one of [1] to [12], wherein the method restores vision in the human patient. [14] The method according to any one of [1] to [12], wherein the method improves the visual acuity of the human patient. [15] The method according to any one of [1] to [14], wherein the antibody comprises a light chain variable domain having an amino acid sequence having at least about 95% homology to an amino acid sequence selected from SEQ ID NOs. 4 and 35 to 38, and the light chain variable domain comprises HVR-L1 having the amino acid sequence of SEQ ID NOs. 5, HVR-L2 having the amino acids of SEQ ID NOs. 6, and HVR-L3 having the amino acids of SEQ ID NOs. 7. [16] The method according to [15], wherein the light chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 4 and 35-38. [17] The method according to any one of [1] to [16], wherein the antibody comprises a heavy chain variable domain having an amino acid sequence having at least about 95% homology to an amino acid sequence selected from SEQ ID NOs. 8 and 31 to 34, and the heavy chain variable domain comprises HVR-H1 having the amino acid sequence of SEQ ID NOs. 9, HVR-H2 having the amino acids of SEQ ID NOs. 10, and HVR-H3 having the amino acids of SEQ ID NOs. 11. [18] The method according to [17], wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NO: 8 and 31-34. [19] The method according to any one of [1] to [18], wherein the antibody is a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, an antibody fragment, or an antibody derivative thereof. [20] The method according to [19], wherein the antibody is an antibody fragment, and the antibody fragment is a Fab fragment, a Fab' fragment, an F(ab')2 fragment, an Fv fragment, a diabody, or a single-chain antibody molecule. [21] The method according to [20], wherein the Fab fragment comprises the heavy chain Fab fragment of SEQ ID NO: 39 and the light chain Fab fragment of SEQ ID NO: 40. [22] The method according to any one of [1] to [21], wherein the antibody is administered once a week. [23] The method according to any one of [1] to [21], wherein the antibody is administered once every two weeks. [24] The method according to any one of [1] to [21], wherein the a